Cogent Biosciences Inc (NAS:COGT)
$ 9.79 -2.08 (-17.52%) Market Cap: 1.07 Bil Enterprise Value: 1.07 Bil PE Ratio: 0 PB Ratio: 4.13 GF Score: 33/100

Cogent Biosciences Inc at Morgan Stanley Global Healthcare Conference Transcript

Sep 13, 2023 / 12:10PM GMT
Release Date Price: $11.5 (-5.58%)
Jason Russell
Morgan Stanley - MD

Good morning, everyone. Welcome to the third and final day of the Morgan Stanley Healthcare Conference. Thanks, everyone, for attending.

My name is Jason Russell with the Healthcare Investment Banking team at Morgan Stanley. Before I jump in and introduce Andy, a quick research disclosure. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/research disclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.

So briefly, on stage here with Andy Robbins, President and CEO of Cogent. Cogent is a clinical-stage company focused on developing precision therapies for genetically-defined diseases. Most advanced clinical program is bezuclastinib. I'm going to try and pronounce that correctly, which is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation, as well as other KIT exon 17 mutations.

Bezu is being studied in systemic

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot